BR9912866A - Composto ou uma forma tautomérica, sal ousolvato farmaceuticamente aceitável do mesmo,composição farmacêutica, processo para otratamento ou a prevenção de uma doença, fatorde risco ou condição, mediada por hppar alfa e/ouhppar gama, e uso de um composto - Google Patents

Composto ou uma forma tautomérica, sal ousolvato farmaceuticamente aceitável do mesmo,composição farmacêutica, processo para otratamento ou a prevenção de uma doença, fatorde risco ou condição, mediada por hppar alfa e/ouhppar gama, e uso de um composto

Info

Publication number
BR9912866A
BR9912866A BR9912866-7A BR9912866A BR9912866A BR 9912866 A BR9912866 A BR 9912866A BR 9912866 A BR9912866 A BR 9912866A BR 9912866 A BR9912866 A BR 9912866A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutically acceptable
hppar
disease
pharmaceutical composition
Prior art date
Application number
BR9912866-7A
Other languages
English (en)
Inventor
Jon Loren Collins
Milana Dezube
Jeffrey Alan Oplinger
Timothy Mark Willson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR9912866A publication Critical patent/BR9912866A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTO OU UMA FORMA TAUTOMéRICA, SAL OUSOLVATO FARMACEUTICAMENTE ACEITáVEL DO MESMO,COMPOSIçãO FARMACêUTICA, PROCESSO PARA OTRATAMENTO OU A PREVENçãO DE UMA DOENçA, FATORDE RISCO OU CONDIçãO, MEDIADA POR hPPAR ALFA E/OUhPPAR GAMA, E USO DE UM COMPOSTO". A presenteinvenção descreve compostos de fórmula (I), e formastautoméricas, sais ou solvatos farmaceuticamente aceitáveis dosmesmos. De preferência, os compostos da invenção consistem deativadores duais de hPPARy e hPPAR<244>.
BR9912866-7A 1998-08-07 1999-08-05 Composto ou uma forma tautomérica, sal ousolvato farmaceuticamente aceitável do mesmo,composição farmacêutica, processo para otratamento ou a prevenção de uma doença, fatorde risco ou condição, mediada por hppar alfa e/ouhppar gama, e uso de um composto BR9912866A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9817118.4A GB9817118D0 (en) 1998-08-07 1998-08-07 Pharmaceutical compounds
PCT/EP1999/005666 WO2000008002A1 (en) 1998-08-07 1999-08-05 SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS hPPAR GAMMA AND hPPAR ALPHA ACTIVATORS

Publications (1)

Publication Number Publication Date
BR9912866A true BR9912866A (pt) 2001-10-30

Family

ID=10836805

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912866-7A BR9912866A (pt) 1998-08-07 1999-08-05 Composto ou uma forma tautomérica, sal ousolvato farmaceuticamente aceitável do mesmo,composição farmacêutica, processo para otratamento ou a prevenção de uma doença, fatorde risco ou condição, mediada por hppar alfa e/ouhppar gama, e uso de um composto

Country Status (31)

Country Link
US (1) US6498174B1 (pt)
EP (1) EP1102757B1 (pt)
JP (1) JP2002522426A (pt)
KR (1) KR20010085340A (pt)
CN (1) CN1321152A (pt)
AP (1) AP2001002066A0 (pt)
AR (1) AR020001A1 (pt)
AT (1) ATE264313T1 (pt)
AU (1) AU5731099A (pt)
BR (1) BR9912866A (pt)
CA (1) CA2339773A1 (pt)
CO (1) CO5070570A1 (pt)
CZ (1) CZ2001490A3 (pt)
DE (1) DE69916457T2 (pt)
EA (1) EA200100105A1 (pt)
EE (1) EE200100074A (pt)
ES (1) ES2220110T3 (pt)
GB (1) GB9817118D0 (pt)
HR (1) HRP20010095A2 (pt)
HU (1) HUP0103469A3 (pt)
ID (1) ID29543A (pt)
IL (1) IL141248A0 (pt)
IS (1) IS5840A (pt)
MA (1) MA26668A1 (pt)
NO (1) NO20010628L (pt)
PE (1) PE20000947A1 (pt)
PL (1) PL345882A1 (pt)
SK (1) SK1962001A3 (pt)
TR (1) TR200100372T2 (pt)
WO (1) WO2000008002A1 (pt)
ZA (1) ZA200100983B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
EP1939188A1 (en) * 1999-09-22 2008-07-02 Bristol-Myers Squibb Company Oxa-and thiazole derivatives useful as antidiabetic and antiobesity agents
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
GB0002667D0 (en) * 2000-02-04 2000-03-29 Glaxo Group Ltd medicamesnts
US20040072838A1 (en) 2000-12-20 2004-04-15 Pierette Banker Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
WO2002076959A1 (fr) * 2001-03-23 2002-10-03 Takeda Chemical Industries, Ltd. Derive heterocyclique a cinq membres d'acide alcanoique
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
SI1392295T1 (sl) 2001-05-15 2006-10-31 Hoffmann La Roche Derivati oksazola, substituirani s karboksilno kislino, za uporabo kot ppar -alfa in -gama aktivatorji pri zdravljenju diabetesa
EP1403253A4 (en) 2001-05-29 2005-03-30 Kyoto Pharma Ind NEW HETEROCYCLIC CONNECTION AND THEIR MEDICAL USE
AU2002308891B2 (en) 2001-05-29 2007-09-06 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic derivatives and medicinal use thereof
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200300681A (en) * 2001-11-12 2003-06-16 Ono Pharmaceutical Co Carboxylic acid derivative compound and medicament containing same as active ingredient
EP1466909A4 (en) 2002-01-17 2005-12-07 Toaeiyo Ltd HALOGENBENZYLAMINOPROPIONSÄUREDERIVATE
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
KR100474202B1 (ko) * 2002-05-04 2005-03-08 강헌중 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체
CA2490152C (en) 2002-07-03 2009-04-07 F. Hoffmann-La Roche Ag Oxazole derivatives and their use as insulin sensitizers
WO2004004665A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
CA2495942C (en) * 2002-08-30 2010-03-23 F. Hoffmann-La Roche Ag Novel 2-arylthiazole compounds as pparalpha and ppargamma agonists
ATE345340T1 (de) 2002-09-12 2006-12-15 Hoffmann La Roche N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
RU2315767C2 (ru) 2002-11-25 2008-01-27 Ф.Хоффманн-Ля Рош Аг Индолилпроизводные, способ их получения, фармацевтическая композиция, способ лечения и/или профилактики заболеваний
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
US7192970B2 (en) 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
KR100730867B1 (ko) 2003-06-20 2007-06-20 에프. 호프만-라 로슈 아게 Ｄｐｐ-ⅳ 억제제로서의 피리도[2,1-ａ]이소퀴놀린 유도체
AU2004251829B2 (en) 2003-06-20 2009-12-17 F. Hoffmann-La Roche Ag Hexahydropyridoisoqinolines as DPP-IV inhibitors
US7825278B2 (en) 2004-05-06 2010-11-02 The Regents Of The University Of California Substituted enaminones, their derivatives and uses thereof
CN100467456C (zh) 2004-05-24 2009-03-11 北京摩力克科技有限公司 作为hPPARα和/或hPPARγ激活剂的α-哌嗪取代的苯丙酸衍生物
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
CN100436430C (zh) * 2004-05-24 2008-11-26 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
CN1896069B (zh) * 2005-07-15 2011-10-05 中国科学院上海药物研究所 一类取代噻唑-4酮化合物、制备方法和用途
CN101007790B (zh) * 2006-01-27 2011-03-30 北京摩力克科技有限公司 草氨酸衍生物、其制备方法和医药用途
WO2007147336A1 (en) * 2006-06-13 2007-12-27 Shanghai Institue Of Materia Medica, Chinese Academy Of Sciences Heterocyclic non-nucleoside compounds, their peparation, pharmaceutical composition and their use as antiviral agents
GB0719180D0 (en) * 2007-10-02 2007-11-14 Cambrex Karlskoga Ab New process
EP2135865A1 (de) 2008-06-17 2009-12-23 Bayer CropScience AG Substituierte 1-(Diazinyl) pyrazol-4-yl-essigsäuren, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
EP2194052A1 (de) 2008-12-06 2010-06-09 Bayer CropScience AG Substituierte 1-(Thiazolyl)- und 1-(Isothiazolyl)pyrazol-4-yl-essigsäuren, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
WO2011073098A1 (de) 2009-12-15 2011-06-23 Bayer Cropscience Ag 1-(heteroaryl)-pyrazol-4-yl-essigsäuren, verfahren zu deren herstellung und deren verwendung als herbizide und pflanzenwachstumsregulatoren
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
WO2022052982A1 (zh) * 2020-09-14 2022-03-17 昭明泽康（北京）生物医药科技有限公司 PPARα（过氧化物酶体增殖物激活受体α）配体在制备药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US6062509A (en) 1994-12-23 2000-05-16 Hexcel Corporation Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports
JPH08325263A (ja) 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−アミノ−３−フェニルプロピオン酸誘導体
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
EE03765B1 (et) * 1996-08-19 2002-06-17 Japan Tobacco Inc. Propioonhappe derivaadid ja nende kasutamine

Also Published As

Publication number Publication date
CA2339773A1 (en) 2000-02-17
MA26668A1 (fr) 2004-12-20
SK1962001A3 (en) 2001-11-06
ZA200100983B (en) 2002-03-05
TR200100372T2 (tr) 2001-09-21
NO20010628L (no) 2001-04-06
US6498174B1 (en) 2002-12-24
EA200100105A1 (ru) 2001-08-27
KR20010085340A (ko) 2001-09-07
AR020001A1 (es) 2002-03-27
EP1102757B1 (en) 2004-04-14
CN1321152A (zh) 2001-11-07
IS5840A (is) 2001-02-05
DE69916457D1 (de) 2004-05-19
CZ2001490A3 (cs) 2001-08-15
AP2001002066A0 (en) 2001-03-31
ES2220110T3 (es) 2004-12-01
EP1102757A1 (en) 2001-05-30
IL141248A0 (en) 2002-03-10
PL345882A1 (en) 2002-01-14
DE69916457T2 (de) 2005-04-14
CO5070570A1 (es) 2001-08-28
HUP0103469A3 (en) 2002-08-28
EE200100074A (et) 2002-06-17
PE20000947A1 (es) 2000-09-22
HUP0103469A2 (hu) 2002-01-28
NO20010628D0 (no) 2001-02-06
HRP20010095A2 (en) 2002-02-28
WO2000008002A1 (en) 2000-02-17
AU5731099A (en) 2000-02-28
GB9817118D0 (en) 1998-10-07
JP2002522426A (ja) 2002-07-23
ID29543A (id) 2001-09-06
ATE264313T1 (de) 2004-04-15

Similar Documents

Publication Publication Date Title
BR9912866A (pt) Composto ou uma forma tautomérica, sal ousolvato farmaceuticamente aceitável do mesmo,composição farmacêutica, processo para otratamento ou a prevenção de uma doença, fatorde risco ou condição, mediada por hppar alfa e/ouhppar gama, e uso de um composto
CY1112024T1 (el) Αναστολεις υποδοχεων adp αιμοπεταλιων
BR0007500A (pt) Composto triazol, fármaco, e, uso do composto
BR0108600A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória
DE69011318T2 (de) Diazinderivate als Angiotensin II Rezeptor Antagonisten.
EA200500853A1 (ru) 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
BR9811482A (pt) Derivados de 1-(n-fenilaminoalquil)-piperazina substituìda na posição 2 do anel fenìlico
CO5271691A1 (es) Nuevos compuestos
DE60115394D1 (de) Benzamide und ähnliche inhibitoren vom faktor xa
ATE204873T1 (de) Naphthyridinderivate als angiotensin-ii- antagonist-inhibitoren
NO20032233D0 (no) Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskul¶re sykdommer
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
TNSN97073A1 (fr) Trihydrate de mesylate de 5-(2-(4-(1,2-benzisothiazole-3-yl)-1- piperazinyl)-etyl)-6-chloro-1,3-dihydro-2 h-indole-2-one, procede pour sa preparation et compositions pharmaceutiques le contenant
ES2080297T3 (es) Derivados 17-g(b)-sustituido-4-aza-5g(a)-androstan-3-ona y procedimiento de preparacion de estos.
BR9606547A (pt) Novos derivados de pirimidona com atividade fungicida
SE9903544D0 (sv) Novel compounds
IT1311922B1 (it) Composti farmaceutici.
BR9812492A (pt) Composto, uso do mesmo, formulação farmacêutica, e, processos para o tratamento de uma doença cardiovascular, para o tratamento de uma vasoconstrição, e para a preparação de compostos
DE69200160D1 (de) Angiotensin-II-Antagonisten.
BR0113389A (pt) Compostos que inibem a atividade do fator xa
BR0113590A (pt) 7-oxo-piridopirimidinas
PT1336407E (pt) Composicao contendo um antagonista do receptor de angiotensina e um diuretico e sua utilizacao para o tratamento da hipertensao
FI935800A0 (fi) Antidepressiva och mot Parkisons sjukdom verksamma foereningar
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
BR9813719A (pt) Agentes terapêuticos

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]